Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659599 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL20281001 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL6473099 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL16431695 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL17866955 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL9985445 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL3281934 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL2338047 | 0.93 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL448041 | 0.93 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL7153437 | 0.93 | AKR1B1 (0.36) | AKR1B1MPITHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4183408-A1 | COMBINED ENTEROTOXIGENIC ESCHERICHIA COLI AND SHIGELLA RECOMBINANT | The United States of America as Represented by The Secretary of the Navy (US) | 2023-05-24 | — | — | EP | claimed |
| EP-3197485-B1 | COMBINED ENTEROTOXIGENIC ESCHERICHIA COLI AND CAMPYLOBACTER JEJUNI RECOMBINANT CONSTRUCT | US NAVY (US) | 2022-11-02 | — | — | EP | claimed |
| US-11077200-B2 | Combined enteropathogen recombinant construct | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2021-08-03 | — | — | US | claimed |
| US-20190008979-A1 | Combined enteropathogen recombinant construct | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2019-01-10 | — | — | US | claimed |
| US-10105448-B2 | Combined enteropathogen recombinant construct | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2018-10-23 | — | — | US | claimed |
| US-20170266300-A9 | Combined enteropathogen recombinant construct | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2017-09-21 | — | — | US | claimed |
| EP-3197485-A1 | COMBINED ENTEROTOXIGENIC ESCHERICHIA COLI AND CAMPYLOBACTER JEJUNI RECOMBINANT CONSTRUCT | The United States of America as Represented by The Secretary of the Navy (US) | 2017-08-02 | — | — | EP | claimed |
| EP-3188748-A1 | IMMUNOGENIC COMPOSITION AGAINST CAMPYLOBACTER JEJUNI | The United States of America as Represented by The Secretary of the Navy (US) | 2017-07-12 | — | — | EP | claimed |
| WO-2016022412-A9 | IMMUNOGENIC COMPOSITION AGAINST CAMPYLOBACTER JEJUNI | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2016-05-12 | — | — | WO | claimed |
| WO-2016048810-A1 | COMBINED ENTEROTOXIGENIC ESCHERICHIA COLI AND CAMPYLOBACTER JEJUNI RECOMBINANT CONSTRUCT | THE UNITED STATES OF AMERICA AS REPRESENTED BY TH SECRETARY OF THE NAVY (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2016022412-A1 | IMMUNOGENIC COMPOSITION AGAINST CAMPYLOBACTER JEJUNI | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2016-02-11 | — | — | WO | claimed |
| US-20150273037-A1 | Immunogenic composition against Campylobacter jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2015-10-01 | — | — | US | claimed |
| US-20150258201-A1 | Combined enteropathogen recombinant construct | GUERRY PATRICIA (US) | 2015-09-17 | — | — | US | claimed |
| EP-2786763-A1 | Capsule composition for use as immunogen against Campylobacter jejuni | The United States of America as Represented by The Secretary of the Navy (US) | 2014-10-08 | — | — | EP | claimed |
| US-7700578-B2 | Capsule composition for use as immunogen against Campylobacter jejuni | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2010-04-20 | — | — | US | claimed |
| US-20090004223-A1 | Capsule composition for use as immunogen against campylobacter jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC. OF THE NAVY | 2009-01-01 | — | — | US | claimed |
| CN-118420796-A | Synthesis method and application of campylobacter jejuni CG8486 capsular oligosaccharide and glycoprotein conjugate thereof | 中国海洋大学 | 2024-08-02 | — | — | CN | disclosed |
| CN-118420796-A | Synthesis method and application of campylobacter jejuni CG8486 capsular oligosaccharide and glycoprotein conjugate thereof | 中国海洋大学 | 2024-08-02 | — | — | CN | disclosed |
| WO-2009017666-A1 | CAPSULE COMPOSITION FOR USE AS IMMUNOGEN AGAINST CAMPYLOBACTER JEJUNI | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090004223-A1 | Capsule composition for use as immunogen against campylobacter jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC. OF THE NAVY | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10105448-B2 | Combined enteropathogen recombinant construct | NOD2, TLR6, TLR2 | AKR1B1 1830/4885MPI 605/4885LMNA 4277/4885 |
| US-20090004223-A1 | Capsule composition for use as immunogen against campylobacter jejuni | ST3GAL3, DDOST, CAPG | AKR1B1 4451/4885MPI 291/4885LMNA 4534/4885 |
| US-20150258201-A1 | Combined enteropathogen recombinant construct | NOD2, TLR6, TLR2 | AKR1B1 1830/4885MPI 605/4885LMNA 4277/4885 |
| US-11077200-B2 | Combined enteropathogen recombinant construct | NOD2, TLR6, TLR2 | AKR1B1 1830/4885MPI 605/4885LMNA 4277/4885 |
| US-20170266300-A9 | Combined enteropathogen recombinant construct | NOD2, TLR6, TLR2 | AKR1B1 1830/4885MPI 605/4885LMNA 4277/4885 |
| US-20150273037-A1 | Immunogenic composition against Campylobacter jejuni | TLR6, TLR2, TLR9 | AKR1B1 3982/4885MPI 221/4885LMNA 3446/4885 |
| US-20190008979-A1 | Combined enteropathogen recombinant construct | NOD2, TLR6, TLR2 | AKR1B1 1830/4885MPI 605/4885LMNA 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.